Sudarshan Pharma Industries Ltd · BSE:SUDARSHAN
Sudarshan Pharma Industries — Investor Presentation (June 2024)
37 slides from Sudarshan Pharma Industries's investor presentation, June 2024
Slide 1: Sudarshan Pharma Industries Limited Investor Presentation
Sudarshan Pharma Industries Limited INVESTOR PRESENTATION June 2024
Slide 2: Disclaimer
Disclaimer This document has been prepared for information purposes only and is not an offer or invitation or recommendation to buy or sell any securities of Sudarshan Pharma Industries Ltd. (“Sudarshan”, “SPIL", "Company”), nor shall part, or all, of this document form the basis of, or be relied on
Slide 3: Table of Content
| Table of Content e ABOUT US BUSINESS INDUSTRY OVERVIEW OVERVIEW 4 5 WAY FINANCIAL FORWARD HIGHLIGHTS Investor Presentation 3
Slide 4: About Us
ABOUT US
Slide 5: About Us
About Us A Specialty Chemicals & Pharmaceutical Manufacturing Company %y Founded in 2008, The Company specializes The company has marked Key clients Sudarshan Pharma in host of products from its presence in India and pharmaceutical Industries Limited (SPIL) is rock chemicals International markets. I
Slide 6: Lead Management
Lead Management Mr. Hemal V. Mehta Mr. Sachin V. Mehta Chairman & Management Director Joint Managing Director & CFO Experience of 16+ years in Sourcing and Supply of Plays a crucial role in sourcing of Specialty Chemicals, Specialty Chemicals, Intermediates, APl and Bulk Drugs. Intermediates & Basic
Slide 7: Board Of Directors
Board Of Directors Umesh Luthra Jaya Sharma Rushabh Patil Anil Ghoghare Independent Director Independent Director Independent Director Non-Executive Director Result oriented Biotech Professional with Registered as an Independent Director Adv. Rushabh Prashant Patil is a Practicing Presently working
Slide 8: Key Personnel
Key Personnel Senior Key Personnel Dr. Vishwas Joshi Mr. Shailesh Bathiya Dr. Siddharth Dr. Shrikant Ghodse Dr. Sanjay Malgundkar Mr. Rajesh Shah - Existing Key Personnel: Mrs. Shrishti Mayekar Mr. Tushar Dholakiya Mr. Manish Chaudhary Sales Head Supply Chain & Trading Production Manager Mr. Shriniv
Slide 9: Milestones
Milestones Incorporated in 2008, the company has achieved new heights every year since 2011. 2011-12 2015-16 2019-20 2023 Generic formulations for * Over 5,000 medical Launch Hart Kit Loading Developing new products institution supply, NGO’s practitioners associated with Dose And Hart Kit4. like Vit
Slide 10: Business Overview
BUSINESS OVERVIEW
Slide 11: Business Model
Business Model Sudarshan Pharma Industries Ltd [ Domestic Market ‘ International Market ] 1 Speciality Chemical Products}—' Direct Marketing J API/Formulations/ Other Pharma Products Speciality API[Formulation | Contract h;:;;l::i':e f‘:,lfi::c . Institutional Chemicals Trading Trading Manufacturing
Slide 12: Key Business Verticals
Key Business Verticals 2. Ethical marketing of branded Contract manufacturing and and unbranded generics in the supply of pharmaceutical domestic pharmaceuticals formulations and medicines for market through our own well-known Pharmaceutical distribution logistics network Companies in India and and
Slide 13: Global Reach
Global Reach 9 Presence Total Export Revenue (INR Mn) 9 5 States @ 57.8 Mn O Office - Mumbai, Maharashtra 0 Plants - Maharashtra - Palghar, Wada Exporting Countries — » Bangladesh » Ghana > Qatar O office 9 Plants » Oman » Somalia > Nepal © RaD . . . . » Saudi Arabia » South Africa » Srilanka » Jord
Slide 14: Our Products
il Our Products 56 out of 96 products * Acetonitrile = Tetrahydrofuran (THF) I} = 1,4-Dioxane = DMF/DMSO ! * Hydrogen Hydride * Diethyl ether 4-methyl Acetophenol 4-methyl benzaldeyde I Investor Presentation
Slide 15: Key Problem Area
Key Problem Area Dependence on China for Import of key APIs Top 5 categories of imports occupy 80% of the share of APl imports India imports ~70% of Intermediate Also, the pandemic which started Imports from Categories required for APls (Active spreading in the previous year China (%) Pharmaceutical
Slide 16: Addressing the Problem
Addressing the Problem The central government has earmarked ~Rs { @ 100 billion for the bulk drug industry, including "‘ Rs 30 billion for the promotion of bulk drug 3 parks (for the next five years) and Rs 69.4 billion for a production-linked incentive scheme for the promotion of domestic manufactu
Slide 17: Business Strengths
Business Strengths 4 N a N\ Established Manufacturing & supply chain for y/ Belief in cost plus formula Chemical, Pharma & \,/ and after sales services. formulation. _ E—, Ny — A 4 N 4 N\ Quality manufacturing 3 Experienced Management facility with Hi-tech team with a dedicated Machines duly approve
Slide 18: Clientele
Clientele o SPECIALTY CHEMICALS PHARMACEUTICAL FORMULATIONS U s sanboz @uecan f} Biocon Cipla Zydus (7acedo» _ 29 /U\EH_ANT —‘v’? CEUS LARSEN@TOUBRO @ Olon i ) g&m U My!eaml:.ne.m. LIFESCIENCES 0 a vz Reliance Industries Limited é' Growth s Life AL KE M “%fi‘;”"‘ Divis Laboratories Lid. | A > @/ < LU
Slide 19: Industry Overview
INDUSTRY OVERVIEW PHARMA INDUSTRY strong in INDIA although highly dependent on CHINA
Slide 20: India - Overview
India - Overview A significant and rising player in the Global Pharmaceutical industry US$ 42 bn 40% 20% India’s pharmaceutical Of generic demand in the US, Of the worldwide supply by market in 2021. It is likely to and 25% of all medicine in the volume and supplying about reach US$ 65 billion by 20
Slide 21: India - a strong exporter of pharma products globally
INDIA- astrong exporter of pharma products Globally v India’s drugs and pharmaceutical exports stood at US$ 24.44 billion in FY21. v India is the 12th largest exporter of medical goods in the world. v The country’'s pharmaceutical sector contributes 6.6% to the total merchandise exports. v Indian dr
Slide 22: Competitive Landscape
Competitive Landscape Formulation Industry owing to high profit margins majority of the company’s competitors are in the formulation export Market Share Formulation Sales in India as of 12 Months ended June 2022 (Rs. mn) Sun Pharma 8.5% Abbatt + Abbott HC + Novo 6.2% w5 Cipla 48% Mankind 47% Zydus 3
Slide 23: Way Forward & Key Developments
WAY FORWARD & KEY DEVELOPMENTS SUDARSHAN PHARMA On the cusp of Transformation
Slide 24: Way Forward
Way Forward READY TO TAKE OFF WITH NEW o T——— PRODUCTS & MARKETS foztprint in the Pharma formulations and medicine in the Domestic and Export markets Focus on Pharma formulations and branded generic medicines through the launch of new products in the Gyeny, Chronic diseases, Gastrointestinal Introdu
Slide 25: New Products & Markets
New Products & Markets New Products for Chemical & Pharma Sector: New Clientele: Chemical Sector: Mac Chem Products (India) Pvt. Ltd. 1 4-MBA, Shilpa Medicare Ltd. 2. 4-methyl Acetophenone, Zyphar's Biopharmaceuticals Pvt. Ltd. 3. 4 6-dichloropyrimidine, Avanscure Life Sciences Pvt. Ltd. 4. Ortho Ph
Slide 26: Key Developments (1/5)
Key Developments (1/5) 1) Investments under the Government PLI Programme The company had received an approval under the PLI scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSM), Drug Intermediates (Dis) and Active Pharmaceutical Ingredients (APIs) in India. Unit 1:
Slide 27: Key Developments (2/5)
Key Developments (2/5) 2) Maharashtra Govt. Subsidies for new project + Pharma Items Manufacturing Project by Sudarshan Group at Mahad MIDC (C Zone) has following subsidy benefits from State Government of Maharashtra, Industries Department , Under PSI-2019 scheme. * Mahad is Under C Zone hence benef
Slide 28: Key Developments (3/5)
Key Developments (3/5) 3) Updates on the new manufacturing Unit 2 + The company has recently setup its Unit 2 at Palghar, Maharashtra. + Key activities at this unit will include from testing of raw materials to dispensing raw materials for formulations, to batch manufacturing as per approved standar
Slide 29: Key Developments (4/5)
Key Developments (4/5) 4) Partnership for distribution of Key Products in India Product 1. Product 2: Product 3: APIs/Intermediates in India Sucralose Beta Hydroxypropyl Methyl Cellulose Cyclodextrin 5 Years (HPMC) Distribution Agreement Low-Substituted Hydroxypropyl uUsD uUsD UsSD USD Cellulose (L-
Slide 30: Key Developments (5/5)
Key Developments (5/5) 5) R&D for New Molecules & New Technology in association with Amity University SPIL has partnered with Dr. William Selvamurthy at Amity University, who has set the benchmark for global education with a system that matches the best practices, theories, resources and standards a
Slide 31: Ratna Lifesciences Pvt Ltd
Ratna Lifesciences Pvt Ltd 100% Rs 55 Million 30 August 2023 Wholly Owned Subsidiary Paid-up Share capital Payable in various tranches Acquisition Completion date Of sudarshan Pharma Industries Ltd. About the company: Existing Products: Capacity: M/s Ratna Lifesciences Private Ltd was - Gemcitabine
Slide 32: Financial Highlights
Financial Highlights
Slide 33: Half-yearly Highlights
Half-yearly Highlights (consolidated) Particulars (INR Mn) H2FY2024 H2FY2023 HoH% Key Business Updates: Net Sales 23174 2,658.4 -12.8% « Organised Global Chem Expo 2023, of pharma professionals year-round through the Total Expenditure 21733 2,580.3 -13.4% company's online platform for strengthening
Slide 34: Annual Income Statement
Annuadl Income Statement (consolidated) Particulars (INR Mn) FY21 FY22 FY23 FY24 Net Sales 19335 3,570.9 4,613.3 4,6354 Total Expenditure 1,861.9 34618 4,466.4 4,407.3 EBITDA 71.6 109.1 146.9 228.1 EBITDA Margin (%) 8T% 31% 3.2% 4.9% Depreciation 74 8.7 91 124 PBIT 64.2 100.5 137.8 215.7 Other Incom
Slide 35: Annual Balance Sheet
Annuadl Balance Sheet (consolidated) Particulars (INR Mn) 24 FY23 Particulars (INR Mn) FY24 FY23 Equity and Liabilities Assets Shareholder's Fund Non-Current Assets Share Capital 2,406.59 2,406.59 Property, Plant, EQuipment & Intangible Assets Reserves & Surplus 8,764.08 7,690.74 - Property, Plant &
Slide 36: Key Financial Charts
Key Financial Charts (consolidated) Revenue from Operations (INR Mn) EBITDA (INR Mn) 5500 200 R 4500 ofo N GR 51 3.5 A 204 150 3 3500 100 2500 1500 50 500 o -500 Fv21 FY22 FY23 Fy24 Y21 Fy22 Fy28 FY24 Profit After Tax (INR Mn) Earnings Per Share (INR) 100 10 80 A3-9°I° ch GR 8 % aA% ch GR 60 6 4 20
Slide 37: Thank You
THANK YOU Sudarshan Pharma Industries Ltd Mr. Nirav Shah, Company Secretary & Compliance Officer Tel: +91-22-4222 1123 | Email: compliance@sudarshanpharma.com www.sudarshanpharma.com
Sudarshan Pharma Industries — Investor Presentation (June 2024) on 6ix